![Nigel McCracken](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nigel McCracken
Geschäftsführer bei
VIRAX BIOLABS GROUP LIMITED
Vermögen: 7 447 $ am 30.06.2026
Profil
Nigel McCracken currently works at Virax Biolabs Group Ltd., as Chief Operating Officer & Director.
Dr. McCracken also formerly worked at Debiopharm International SA, as Executive Director & VP-Translational Medicine from 2014 to 2019, NuCana Plc, as COO, Senior VP-Discovery & Early Development, and BerGenBio ASA, as Chief Scientific Officer from 2021 to 2023.
Dr. McCracken received his undergraduate degree from the University of Strathclyde and graduate degree from King's College London.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 02.07.2026 | 2 533 ( 0,32 % ) | 7 447 $ | 30.06.2026 |
Aktive Positionen von Nigel McCracken
| Unternehmen | Position | Beginn |
|---|---|---|
| VIRAX BIOLABS GROUP LIMITED | Geschäftsführer | 01.09.2023 |
Ehemalige bekannte Positionen von Nigel McCracken
| Unternehmen | Position | Ende |
|---|---|---|
| ONCOINVENT ASA | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2023 |
Debiopharm International SA
 Debiopharm International SA BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops drugs to cure cancer and infectious diseases | Direktor/Vorstandsmitglied | 01.04.2019 |
| NUCANA PLC | Geschäftsführer | - |
Ausbildung von Nigel McCracken
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
5
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Debiopharm International SA
Debiopharm International SA BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops drugs to cure cancer and infectious diseases | Health Technology |
University of Strathclyde
 University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
King's College London
 King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BerGenBio ASA
 BerGenBio ASA Pharmaceuticals: MajorHealth Technology Develops drugs for aggressive, drug resistant cancers | Health Technology |
NuCana Plc
 NuCana Plc BiotechnologyHealth Technology Develops and commercializes novel anti-cancer medicines | Health Technology |
Virax Biolabs Group Ltd.
 Virax Biolabs Group Ltd. Financial ConglomeratesFinance Develops and distributes immunology software, platform and medical devices | Finance |
